-
Shenzhen Eureka Biotechnology Secures RMB 300 Million in Series B+ Funding for CGT Expansion
•
Shenzhen Eureka Biotechnology Co., Ltd., a specialist in cell and gene therapy (CGT) based in China, has successfully raised over RMB 300 million (approximately USD 41.7 million) in a Series B+ financing round. The funding was led by Yuexiu Capital, with notable participation from Fortune Capital, Guangdong Technology Financial Group,…
-
Biosmelt Pharma Partners with Shenzhen Eureka Biotechnology for Cell and Gene Therapy Advancements
•
Shanghai-based cell and gene therapy (CGT) specialist, Biosmelt Pharma, has entered into a partnership with Shenzhen Eureka Biotechnology Co., Ltd, a domestic CGT-focused Contract Development and Manufacturing Organization (CDMO) service provider. Combining Expertise for Large-Scale Virus Vector ProductionThe collaboration aims to capitalize on Biosmelt’s GMP grade lentivirus vector suspension production…
